[Antithrombin III control in patients with long-term anticoagulant therapy].

J F Hönig, H A Merten, O Korth, F Halling, H Köstering
{"title":"[Antithrombin III control in patients with long-term anticoagulant therapy].","authors":"J F Hönig,&nbsp;H A Merten,&nbsp;O Korth,&nbsp;F Halling,&nbsp;H Köstering","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>Antithrombin III and protein C are the major inhibitors of the plasma clotting system. Since adequate thromboembolism protection requires a cofactor AT III for heparin to provide full antithrombotic coverage, the preoperative AT III and protein C levels in the plasma of 105 patients treated with marcumar are measured. The understanding of the physiological role of these inhibitors of the plasma clotting system and of the causes for their decrease should directly lead to the indications for laboratory analysis.</p>","PeriodicalId":77522,"journal":{"name":"Deutsche Zeitschrift fur Mund-, Kiefer- und Gesichts-Chirurgie","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"1991-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Deutsche Zeitschrift fur Mund-, Kiefer- und Gesichts-Chirurgie","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Antithrombin III and protein C are the major inhibitors of the plasma clotting system. Since adequate thromboembolism protection requires a cofactor AT III for heparin to provide full antithrombotic coverage, the preoperative AT III and protein C levels in the plasma of 105 patients treated with marcumar are measured. The understanding of the physiological role of these inhibitors of the plasma clotting system and of the causes for their decrease should directly lead to the indications for laboratory analysis.

[长期抗凝治疗患者的抗凝血酶III控制]。
抗凝血酶III和蛋白C是血浆凝血系统的主要抑制剂。由于充分的血栓栓塞保护需要肝素辅助因子AT III来提供充分的抗血栓覆盖,因此我们测量了105例瘤状细胞瘤患者术前AT III和血浆蛋白C水平。了解这些血浆凝血系统抑制剂的生理作用及其降低的原因应直接导致实验室分析的适应症。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信